A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

Michael,M.; Pavlakis,N.; Clingan,P.; De Boer,R.; Johnston,M.; Clarke,S.

doi:10.3892/or.2012.1871

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

Authors:
- M. Michael
- N. Pavlakis
- P. Clingan
- R. De Boer
- M. Johnston
- S. Clarke
View Affiliations

Affiliations: Division of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia, Royal North Shore Hospital, St Leonards, Australia, Southern Medical Day Care, Wollongong, Australia, Royal Melbourne Hospital, Parkville, Australia, Roche Products, Dee Why, Australia, Concord Repatriation General Hospital, Concord, Australia
Published online on: June 15, 2012 https://doi.org/10.3892/or.2012.1871
Pages: 763-767
Copyright: © Michael et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Erlotinib and gemcitabine are active in NSCLC and have synergy in other cancers. This study investigated the activity and tolerability of this combination as first-line therapy in ECOG PS 2 patients. Chemotherapy-naïve patients with NSCLC, either stage IIIB (with plural effusion) or stage IV, with measurable disease and ECOG PS 2, and adequate organ function were randomized to receive either erlotinib (150 mg/day p.o.) plus gemcitabine (1000 mg/m2, days 1, 8, 15, every 4 weeks) in Arm A or gemcitabine monotherapy (Arm B). The primary end-point was progression-free survival. Seventeen patients of a planned 120 patients were randomized (12 males; 16 Caucasians, 4 large cell, 9 adenocarcinoma; 13 former and 1 never smokers); 16 patients received treatment (8 in each arm). The incidence of treatment-related adverse events (AEs) was 8/8 in Arm A and 6/8 in Arm B; most AEs were grade 1 or 2. The most common treatment-related non-hematological AEs were grade 1 or 2 rash (7/8) and diarrhea (7/8) in Arm A. Two patients in Arm A had partial responses, with durations of 16 and 47 weeks, respectively. Overall disease control rate (N=15) was 86% in Arm A versus 50% for the control arm. Erlotinib plus gemcitabine for the treatment of ECOG 2 NSCLC patients warrants further investigation including intermittent erlotinib regimens.

View Figures

View References

1	Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 47:87–98. 1991.PubMed/NCBI
2	Veale D, Ashcroft T, Marsh C, Gibson GJ and Harris A: Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 55:513–516. 1987. View Article : Google Scholar : PubMed/NCBI
3	Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 291:739–748. 1999.
4	Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:4838–4848. 1997.PubMed/NCBI
5	Bezjak A, Tu D, Seymour L, et al: Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 24:3831–3837. 2006. View Article : Google Scholar
6	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
7	Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced mon-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 25:1545–1552. 2007. View Article : Google Scholar : PubMed/NCBI
8	Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 23:5892–5899. 2005. View Article : Google Scholar
9	Kosmidis PA, Dimopoulos MA, Syrigos K, et al: Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol. 2:135–140. 2007. View Article : Google Scholar
10	Langer CJ, O’Byrne KJ, Socinski MA, et al: Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 3:623–630. 2008.PubMed/NCBI
11	O’Brien ME, Socinski MA, Popovich AY, et al: Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 3:728–734. 2008.PubMed/NCBI
12	Lilenbaum R, Villaflor VM, Langer C, et al: Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 4:869–874. 2009. View Article : Google Scholar
13	Quoix E, Oster V, Westeel E, et al: Weekly paclitaxel combined with monthly carboplatin versus single agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 28(Suppl S18): abs. 122010.
14	Mok TSK, Wu Y-L, Yu C-Y, et al: Randomized, placebo-controlled Phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small cell lung cancer. J Clin Oncol. 27:5080–5087. 2009. View Article : Google Scholar : PubMed/NCBI
15	Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar
16	Pocock SJ and Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics. 31:103–115. 1975. View Article : Google Scholar : PubMed/NCBI
17	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
18	Pérez-Soler R, Chachoua A, Hammond L, et al: Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol. 22:3238–3247. 2004.PubMed/NCBI
19	Stinchcombe T, Bradford DS, Lee CB, et al: Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 28(Suppl S15): abs. 75762010.
20	Li T, Ling YH, Goldman ID and Perez-Soler R: Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 13:3413–3422. 2007. View Article : Google Scholar : PubMed/NCBI
21	Davies AM, Hesketh PJ, Beckett L, et al: Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonism. J Clin Oncol. 25(Suppl S18): abs. 76182007.
22	Davies AM, Ho C, Beckett L, et al: Intermittent erlotinib (ERL) in combination with pemetrexed (PEM): phase I schedules designed to achieve pharmacodynamic separation. J Clin Oncol. 26(Suppl): abs. 80322008.
23	Li T, Lara PN Jr, Mack PC, Perez-Soler R and Gandara D: Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. Curr Drug Targets. 11:85–94. 2010. View Article : Google Scholar : PubMed/NCBI
24	Gridelli C, Morabito A, Gebbia V, et al: Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: the cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer. 67:86–92. 2010. View Article : Google Scholar : PubMed/NCBI